IP Library Granted Patent US 6,939,298
Granted Patent B2
US 6,939,298 · App. 10/376,793 · Granted Sep 6, 2005

Device and method for monitoring aqueous flow within the eye

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,939,298
App. No.
10/376,793
Granted
Sep 6, 2005
Kind
B2
Abstract

The present invention provides a device and method for monitoring the flow of aqueous humor within the eye. The invention provides that the aqueous flow rate and/or pattern within the anatomical structures of the eye can be determined by monitoring a traceable component. Such determination provides diagnostic indications of the degree and location of ocular disease associated with aqueous outflow, such as glaucoma, and can further provide post-treatment indications of effectiveness.

Claims (30)

1. A method of determining a pattern and extent of aqueous outflow in the eye, comprising monitoring the flow of aqueous humor in an anatomical structure of the eye associated with aqueous humor flow, wherein monitoring the flow of aqueous humor comprises the steps of:

a) measuring the flow of aqueous humor at a first anatomical structure of the eye associated with aqueous humor flow; and

b) comparing the flow of aqueous humor at the first anatomical structure to the flow of aqueous humor at a second anatomical structure of the eye associated with aqueous humor flow

to thereby monitor the flow of aqueous humor wherein the flow of aqueous humor is determined relative to observation of a monitored flow of a traceable component.

2. The method of claim 1 , wherein the traceable component is administered topically.

3. The method of claim 1 , wherein the traceable component is administered directly into the anterior chamber.

4. The method of claim 1 , wherein the traceable component is administered directly into an anatomical structure of the eye associated with aqueous humor flow, selected from the group comprising an anterior chamber, a trabecular meshwork, a Schlemm's canal, a collecting channel, an aqueous vein, and an episcleral vein.

5. The method of claim 1 , wherein the traceable component is selected from the group consisting of a colored dye, a radiopaque dye, a fluorescing compound, a radioisotope, and a gaseous precursor filled microsphere.

6. The method of claim 1 , wherein monitoring the flow of aqueous humor is performed without the administration of an exogenous traceable component.

7. The method of claim 1 , wherein the monitoring step identifies an aqueous outflow obstruction in an eye of a patient with glaucoma.

8. The method of claim 1 , wherein the monitoring step identifies a response to therapeutic intervention in an eye of a patient with glaucoma.

9. A method of determining a pattern and extent of aqueous outflow in the eye, comprising monitoring the flow of aqueous humor in an anatomical structure of the eye associated with aqueous humor flow, wherein monitoring the flow of aqueous humor comprises the steps of:

a) measuring the flow of aqueous humor at a first location in an anatomical structure of the eye associated with aqueous humor flow; and

b) comparing the flow of aqueous humor at the first location in an anatomical structure of the eye to the flow of aqueous humor at a second location in the same anatomical structure of the eye

wherein the flow of aqueous humor is determined relative to observation of a monitored flow of a traceable component.

10. The method of claim 9 , wherein the traceable component is administered topically.

11. The method of claim 9 , wherein the traceable component is administered directly into the anterior chamber.

12. The method of claim 9 , wherein the traceable component is administered directly into an anatomical structure of the eye associated with aqueous humor flow, selected from the group comprising an anterior chamber, a trabecular meshwork, a Schlemm's canal, a collecting channel, an aqueous vein, and an episcleral vein.

13. The method of claim 9 , wherein the traceable component is selected from the group consisting of a colored dye, a radiopaque dye, a fluorescing compound, a radioisotope, and a gaseous precursor filled microsphere.

14. The method of claim 9 , wherein monitoring the flow of aqueous humor is performed without the administration of an exogenous traceable component.

15. The method of claim 9 , wherein the monitoring step identifies an aqueous outflow obstruction in an eye of a patient with glaucoma.

16. The method of claim 9 , wherein the monitoring step identifies a response to therapeutic intervention in an eye of a patient with glaucoma.

17. A method of determining a pattern and extent of aqueous outflow in the eye, comprising monitoring the flow of aqueous humor in an anatomical structure of the eye associated with aqueous humor flow, wherein monitoring the flow of aqueous humor comprises the steps of:

a) measuring the flow of aqueous humor at a first location in an anatomical structure of the eye associated with aqueous humor flow; and

b) comparing the flow of aqueous humor at the first location to the flow of aqueous humor at the first location after a period of time,

wherein the flow of aqueous humor is determined relative to observation of a monitored flow of a traceable component, and wherein the traceable component is administered directly into the anterior chamber.

18. The method of claim 17 , wherein the traceable component is selected from the group consisting of a colored dye, a radiopaque dye, a fluorescing compound, a radioisotope, and a gaseous precursor filled microsphere.

19. The method of claim 17 , wherein monitoring the flow of aqueous humor is performed without the administration of an exogenous traceable component.

20. The method of claim 17 , wherein the monitoring step identifies an aqueous outflow obstruction in an eye of a patient with glaucoma.

21. The method of claim 17 , wherein the monitoring step identifies a response to therapeutic intervention in an eye of a patient with glaucoma.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2007
From: GMP VISION SOLUTIONS, INC.
To: GLAUKOS CORPORATION
Reel/Frame 018816/0050 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2003
From: BROWN, REAY H.; LYNCH, MARY G.
To: GMP VISION SOLUTIONS, INC.
Reel/Frame 014211/0026 →